Madrigal Pharmaceuticals, Inc. (MDGL)

$222.26

-6.08

(-2.66%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Madrigal Pharmaceuticals, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 67.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 162.1%

Performance

  • $220.74
    $227.31
    $222.26
    downward going graph

    0.68%

    Downside

    Day's Volatility :2.89%

    Upside

    2.22%

    downward going graph
  • $119.76
    $322.67
    $222.26
    downward going graph

    46.12%

    Downside

    52 Weeks Volatility :62.88%

    Upside

    31.12%

    downward going graph

Returns

PeriodMadrigal Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
1.89%
-0.7%
0.0%
6 Months
67.77%
6.6%
0.0%
1 Year
-21.08%
3.7%
-1.5%
3 Years
88.41%
14.0%
-21.8%

Highlights

Market Capitalization
4.9B
Book Value
$20.39
Earnings Per Share (EPS)
-19.99
PEG Ratio
0.0
Wall Street Target Price
394.54
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-47.41%
Return On Equity TTM
-123.98%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-380.0M
Diluted Eps TTM
-19.99
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-23.48
EPS Estimate Next Year
-14.46
EPS Estimate Current Quarter
-5.28
EPS Estimate Next Quarter
-5.05

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Madrigal Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
15
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 77.51%

Current $222.26
Target $394.54

Technicals Summary

Sell

Neutral

Buy

Madrigal Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
-19.38%
67.77%
-21.08%
88.41%
116.31%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
NA
NA
0.0
-23.48
-1.24
-0.47
NA
20.39
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
Buy
$4.9B
116.31%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • HHG PLC

    14.06%
  • Baker Bros Advisors LP

    9.54%
  • venBio Select Advisor LLC

    9.15%
  • Vanguard Group Inc

    7.63%
  • BlackRock Inc

    5.87%
  • RTW INVESTMENTS, LLC

    3.95%

Corporate Announcements

  • Madrigal Pharmaceuticals, Inc. Earnings

    Madrigal Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.

Organization
Madrigal Pharmaceuticals, Inc.
Employees
376
CEO
Dr. Rebecca A. Taub M.D.
Industry
Health Technology

FAQs